SCHEMBL3593211

SCHEMBL3593211

CC(C)(C)OC(=O)NCCNC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 1/20 0.58
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
NPFFR1 Q9GZQ6 1/20 0.55
NPFFR2 Q9Y5X5 1/20 0.55
ACHE P22303 4/20 0.53
BACE1 P56817 3/20 0.53
BCHE P06276 1/20 0.53
MAOB P27338 2/20 0.53
SIGMAR1 Q99720 2/20 0.52
DRD4 P21917 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
SLC6A3 Q01959 1/20 0.52
POLB P06746 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MCHR1 Q99705 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9884890 0.92 KMT2A (0.50) KDM4EALDH1A1KMT2AMEN1NPFFR1
SCHEMBL803459 0.87 ACHE (0.67) ACHEMAOB
SCHEMBL13245164 0.86 PRKAA2 (0.53) ALDH1A1KMT2AMEN1ACHEMAOB
SCHEMBL4039589 0.86 MCHR1 (0.56) KDM4EALDH1A1KMT2AMEN1SIGMAR1
SCHEMBL915402 0.85 KMT2A (0.65) KMT2AMEN1MAOBSIGMAR1DRD4
SCHEMBL30049396 0.85 ACHE (0.58) NPFFR1NPFFR2ACHEBCHE
SCHEMBL3635817 0.84 KMT2A (0.56) KDM4EKMT2AMEN1BCHEMAOB
SCHEMBL4730142 0.84 SIGMAR1 (0.62) KMT2AMEN1NPFFR1NPFFR2SIGMAR1
SCHEMBL3052457 0.83 HDAC3 (0.59) ACHEBCHEMAOBDRD4
SCHEMBL5711288 0.83 MAOB (0.60) KMT2AMEN1ACHEBACE1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069417-A1 NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-03-18 US disclosed
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed
EP-1904479-A2 NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS Sanofi-Aventis (FR) 2008-04-02 EP disclosed
WO-2007006926-A2 NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069417-A1 NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS IKBKB, NFKBIA, IKBKE KDM4E 648/4885ALDH1A1 4662/4885KMT2A 1238/4885
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE KDM4E 1295/4885ALDH1A1 3661/4885KMT2A 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.